1Clinical Pharmacy Department, University of Baghdad, College of Pharmacy
2Clinical Biochemistry Department, University of Baghdad, College of Pharmacy
3Iraqi Medical Board of Neurology Baghdad Teaching Hospital, Baghdad, Iraq
The 25-hydroxy cholecalciferol is an immune system modulator which is usually low in majority of multiple sclerosis patients. The aim of the study determine serum 25-hydroxycholecalciferol level in addition to a specific therapy in patients with multiple sclerosis and its correlation with disease activity through determining disease primary and secondary outcomes (MRI data, disease relapse, and exacerbations, EDSS, and quality of life scores).A total of 215 MS participants aged between 18 and 65 were enrolled in the study and divided into 2 groups. The first group of 148 patients received various doses of vitamin D supplements while the second group of 67 patients did not receive vitamin D. The study was implemented for six months of follow up. Blood samples were taken every two months and MRI data, EDSS score, disease exacerbation data as well as the quality of life score was obtained and recorded throughout the study time period. The result shows mean 25-hydroxy cholecalciferol concentrations were associated significantly with the mean quality of life score. Some disease exacerbations were also improved significantly (P < 0.05), however, no significant association was found with EDSS score, MRI outcomes, and relapse rate.
Multiple sclerosis, vitamin D
